Zuclopenthixol acetate (5% in 'Viscoleo'): single-dose treatment for acutely disturbed psychotic patients.
Twenty-five acutely disturbed psychotic patients were treated in an open study with a single injection of zuclopenthixol acetate 5% in 'Viscoleo, a thin vegetable oil. Patients were assessed post-injection for 3 days using the BPRS, CGI, and a specially designed behaviour/activity scale. Doses of 50 to 150 mg proved effective in 24 (96%) of 25 patients, with pronounced and rapid reduction in psychotic symptoms over the study period. The mean total BPRS score after 72 hours was reduced by over 57%. Tranquillization and sedation appeared within 15 to 90 minutes of injection. Unwanted symptoms were generally mild and of low incidence. The results showed that a single injection of zuclopenthixol acetate 5% in 'Viscoleo' provided rapid tranquillization and sedation coupled with an antipsychotic effect over 3 days. This profile offers a distinct advantage over neuroleptic preparations conventionally used for the initial treatment of acutely disturbed psychotic patients.
Chakravarti
S K
SK
Dewsbury District Hospital, England.
Muthu
A
A
Muthu
P K
PK
Naik
P
P
Pinto
R T
RT
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003006:Clopenthixol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy*; D013892:Thioxanthenes / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D013892:Thioxanthenes; C060342:clopenthixol acetate ester; D003006:Clopenthixol